LeMaitre Vascular (NASDAQ:LMAT) Downgraded by Barrington Research to “Market Perform”

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by stock analysts at Barrington Research from an “outperform” rating to a “market perform” rating in a note issued to investors on Friday, MarketBeat.com reports.

Other research analysts have also recently issued research reports about the stock. Oppenheimer restated an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective for the company. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.63.

LeMaitre Vascular Trading Down 3.0 %

Shares of LeMaitre Vascular stock opened at $99.91 on Friday. LeMaitre Vascular has a twelve month low of $62.39 and a twelve month high of $109.58. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of 54.60, a PEG ratio of 2.22 and a beta of 0.96. The business’s 50 day simple moving average is $96.90 and its 200-day simple moving average is $94.66.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting the consensus estimate of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million for the quarter, compared to analyst estimates of $55.99 million. Sell-side analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Institutional Investors Weigh In On LeMaitre Vascular

A number of institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new stake in shares of LeMaitre Vascular in the fourth quarter valued at $14,900,000. Rockefeller Capital Management L.P. bought a new stake in LeMaitre Vascular in the fourth quarter worth about $7,787,000. Segall Bryant & Hamill LLC bought a new stake in LeMaitre Vascular in the fourth quarter worth about $5,446,000. Invesco Ltd. boosted its position in shares of LeMaitre Vascular by 50.5% during the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock valued at $16,124,000 after purchasing an additional 58,720 shares in the last quarter. Finally, DF Dent & Co. Inc. boosted its position in shares of LeMaitre Vascular by 26.2% during the 3rd quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock valued at $24,037,000 after purchasing an additional 53,797 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.